Synapse - Eileen O'Reilly

Results (790)

Improving understanding of pancreatic cancer among patients using an animated patient's guide to benefit informed decisions and health outcomes

Meeting Abstract

Munigala, S.; O'Reilly, E. M.; Bakelman, D. E.; Holt, J.; Ko, A. H.; Searle, N.; Gelrud, A.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Circulating KRAS variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving chemoimmunotherapy

Meeting Abstract

Till, J. E.; McDaniel, L.; Pfeiffer, S. M.; Maurer, D. M.; Yu, J.; Spencer, C.; Lyman, J. P.; Cabanski, C. R.; Da Silva, D. M.; Abbott, C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers

Meeting Abstract

Schram, A. M.; Goto, K.; Kim, D. W.; Martin-Romano, P.; Ou, S. H. I.; O'Kane, G. M.; O'Reilly, E. M.; Umemoto, K.; Duruisseaux, M.; Neuzillet, C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors

Meeting Abstract

Pant, S.; Furqan, M.; Abdul-Karim, R. M.; Chung, V.; Devoe, C. E.; Johnson, M. L.; Leal, A. D.; Park, H.; Wainberg, Z. A.; Welkowsky, E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study

Meeting Abstract

Park, W.; O'Reilly, E. M.; Furuse, J.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Lee, H. J.; Kunieda, F.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade

Meeting Abstract

Park, W.; Keane, F.; Bandlamudi, C.; Donoghue, M.; de Lara, P. T.; Harding, J. J.; Khalil, D.; McKinnell, Z.; Sterpi, M.; Cao, W.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer

Meeting Abstract

Padrón, L. J.; Maurer, D. M.; O'Hara, M. H.; O'Reilly, E. M.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G. A.; Rahma, O. E.; Lyman, J. P.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Phase III study (daNIS-2) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

Meeting Abstract

O'Reilly, E. M.; Golan, T.; Ikeda, M.; Milella, M.; Taieb, J.; Wainberg, Z. A.; Wang, L. W.; Gyambibi, N.; Lopez-Martin, E. M.; Xu, K.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance)

Meeting Abstract

Kohn, C. G.; Ou, F. S.; Ma, C.; Larson, N. B.; Zemla, T. J.; Yuan, C.; Niedzwiecki, D.; Hollis, B. W.; Nixon, A. B.; Lenz, H. J.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors

Meeting Abstract

Kelley, R. K.; Van Cutsem, E.; Lee, M. S.; Wolf, I.; Fakih, M.; De Vos-Geelen, J. D.; Lee, V.; Vogel, A.; Wu, L.; Jin, F.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save